Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD2 | O14939 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312238 | 1.00 | PLD2 (0.44) | PLD2PLD1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12012710 | 0.95 | CHRNB2 (0.45) | PLD2PLD1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1312476 | 0.92 | PLD2 (0.45) | PLD2PLD1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1313566 | 0.92 | PLD2 (0.45) | PLD2PLD1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1312652 | 0.91 | PLD2 (0.48) | PLD2PLD1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1312579 | 0.88 | CHRNB2 (0.53) | PLD2PLD1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1315261 | 0.84 | HDAC6 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4HDAC6 | |
| SCHEMBL1311762 | 0.84 | KDM4E (0.48) | PLD2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1314901 | 0.83 | KDM4E (0.49) | PLD2PLD1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL17004616 | 0.83 | MEN1 (0.46) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252790-B2 | Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity | RAQUALIA PHARMA INC. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| WO-2010058858-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | ラクオリア創薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | PLD2 2008/4885PLD1 2967/4885CHRNB2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.